Abstract
bHepatitis C viral infection is a common cause of liver disease among polytransfused
patients.
Aim of the study: To find out short term efficacy of Interferon therapy in thalassemic chronic viral
hepatitis-C patients.
Setting: This study was carried out in Gastroenterology and Hepatology Teaching hospital in Baghdad –
Iraq
Patients and methods:Twenty four thalassemic patients who were anti HCV antibody positive with
elevated liver enzyme for more than one year enrolled in this study . All patients were submitted to liver
biopsy to assess the degree of the inflammation and fibrosis .All patients were treated with interferon
alpha (3 ×106 units/m2) tree times a week for six months.
Result: Three out of twenty four patients stopped treatments because of sever side effect. Out of twenty
one patients; 10(47 %) of patients showed complete biochemical response, 7(33%) of patients showed
partial biochemical response, 4(19%) of patients showed no response.
Young age patients responded better to interferon therapy .patients with initial high serum alanine
trasaminase responded less favorably than those who had lower initial pretreatment serum alanine
transaminase ,this was statistically significant .The higher the initial serum ferritine the worst the
biochemical and histological response .All patients who responded biochemically and submitted to
another liver biopsy showed decrease in severity of histological activity index after six months of
Interferon therapy ;there was strong correlation between biochemical response and histological response.
There was no improvement in degree of fibrosis in those treated with interferon therapy.Splenectomized
patient tolerated better and responded better than those who were not splenectomized .
Conclution:Thalassemic patients with chronic viral hepatitis C can benefit at least in short term from
Interferon therapy especially
in younger age patients and those who have lowest elevation of liver
enzymes and those with lower serum ferritin level.
patients.
Aim of the study: To find out short term efficacy of Interferon therapy in thalassemic chronic viral
hepatitis-C patients.
Setting: This study was carried out in Gastroenterology and Hepatology Teaching hospital in Baghdad –
Iraq
Patients and methods:Twenty four thalassemic patients who were anti HCV antibody positive with
elevated liver enzyme for more than one year enrolled in this study . All patients were submitted to liver
biopsy to assess the degree of the inflammation and fibrosis .All patients were treated with interferon
alpha (3 ×106 units/m2) tree times a week for six months.
Result: Three out of twenty four patients stopped treatments because of sever side effect. Out of twenty
one patients; 10(47 %) of patients showed complete biochemical response, 7(33%) of patients showed
partial biochemical response, 4(19%) of patients showed no response.
Young age patients responded better to interferon therapy .patients with initial high serum alanine
trasaminase responded less favorably than those who had lower initial pretreatment serum alanine
transaminase ,this was statistically significant .The higher the initial serum ferritine the worst the
biochemical and histological response .All patients who responded biochemically and submitted to
another liver biopsy showed decrease in severity of histological activity index after six months of
Interferon therapy ;there was strong correlation between biochemical response and histological response.
There was no improvement in degree of fibrosis in those treated with interferon therapy.Splenectomized
patient tolerated better and responded better than those who were not splenectomized .
Conclution:Thalassemic patients with chronic viral hepatitis C can benefit at least in short term from
Interferon therapy especially
in younger age patients and those who have lowest elevation of liver
enzymes and those with lower serum ferritin level.